Skip to search formSkip to main contentSkip to account menu

lubiprostone

Known as: 7-((1R,4R,6R,9R)-4-(1,1-difluoropentyl)-4-hydroxy-8-oxo-5-oxabicyclo(4.3.0)non-9-yl)heptanoic acid, Lubiprostone [Chemical/Ingredient], Prostan-1-oic acid, 16,16-difluoro-11-hydroxy-9,15-dioxo-, (11alpha)- 
A bicyclic fatty acid derived from prostaglandin E1 and a chloride channel activator with laxative activity. Upon intake, lubiprostone specifically… 
National Institutes of Health

Related topics

Related topics

13 relations

Broader (2)

AmitizaChloride Channel Agonists
In Bloodagonistsanalogs & derivativesantagonists & inhibitors

Narrower (2)

RU 0211SPI 0211

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Efficacy of Treatments for Opioid‐Induced Constipation: Systematic Review and Meta‐analysis
Review
2016
Review
2016
Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline
Abstract Objective To formulate timely evidence-based guidelines for the management of opioid-induced bowel dysfunction. Setting… 
Review
2016
Review
2016
Opioid-induced constipation: advances and clinical guidance
Currently opioids are the most frequently used medications for chronic noncancer pain. Opioid-induced constipation is the most… 
Review
2015
Review
2015
Current developments in pharmacological therapeutics for chronic constipation
Highly Cited
2014
Highly Cited
2014
Lubiprostone for the Treatment of Functional Constipation in Children
Objectives: Pediatric functional constipation is common; effective, easily administered treatment options are limited… 
Highly Cited
2011
Highly Cited
2011
World Gastroenterology Organisation global guideline: Constipation--a global perspective.
INTRODUCTION Constipation is a chronic problem in many patients all over the world. In some groups of patients such as the… 
Highly Cited
2009
Highly Cited
2009
Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
BACKGROUND & AIMS Lubiprostone alleviates constipation by stimulating intestinal fluid secretion, purportedly through activation… 
Highly Cited
2008
Highly Cited
2008
Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon
Background and purpose: Lubiprostone (Amitiza), a possible ClC‐2 channel opener derived from prostaglandin E1 and indicated for… 
Highly Cited
2007
Highly Cited
2007
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double‐blind, placebo‐controlled, dose‐ranging study to evaluate efficacy and safety
Lubiprostone, a locally acting type‐2 chloride channel activator, induces intestinal fluid secretion. 
Review
2007
Review
2007
Constipation in long-term care.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)